CLYYF
Price
$0.41
Change
-$0.12 (-22.64%)
Updated
Aug 12 closing price
Capitalization
8.98M
Intraday BUY SELL Signals
IBIO
Price
$2.08
Change
-$0.16 (-7.14%)
Updated
Feb 4, 02:49 PM (EDT)
Capitalization
50.15M
Intraday BUY SELL Signals
Interact to see
Advertisement

CLYYF vs IBIO

Header iconCLYYF vs IBIO Comparison
Open Charts CLYYF vs IBIOBanner chart's image
Celyad Oncology SA
Price$0.41
Change-$0.12 (-22.64%)
Volume$600
Capitalization8.98M
iBio
Price$2.08
Change-$0.16 (-7.14%)
Volume$1.33K
Capitalization50.15M
CLYYF vs IBIO Comparison Chart in %
CLYYF
Daily Signal:
Gain/Loss:
IBIO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CLYYF vs. IBIO commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLYYF is a Hold and IBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (CLYYF: $0.15 vs. IBIO: $2.24)
Brand notoriety: CLYYF and IBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLYYF: 101% vs. IBIO: 12%
Market capitalization -- CLYYF: $8.98M vs. IBIO: $50.15M
CLYYF [@Biotechnology] is valued at $8.98M. IBIO’s [@Biotechnology] market capitalization is $50.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLYYF’s FA Score shows that 0 FA rating(s) are green whileIBIO’s FA Score has 0 green FA rating(s).

  • CLYYF’s FA Score: 0 green, 5 red.
  • IBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, IBIO is a better buy in the long-term than CLYYF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLYYF’s TA Score shows that 2 TA indicator(s) are bullish while IBIO’s TA Score has 3 bullish TA indicator(s).

  • CLYYF’s TA Score: 2 bullish, 1 bearish.
  • IBIO’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CLYYF is a better buy in the short-term than IBIO.

Price Growth

CLYYF (@Biotechnology) experienced а 0.00% price change this week, while IBIO (@Biotechnology) price change was -1.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBIO($50.1M) has a higher market cap than CLYYF($8.98M). IBIO YTD gains are higher at: 16.062 vs. CLYYF (0.000).
CLYYFIBIOCLYYF / IBIO
Capitalization8.98M50.1M18%
EBITDAN/A-18.78M-
Gain YTD0.00016.062-
P/E RatioN/A0.65-
RevenueN/A500K-
Total CashN/A49.6M-
Total DebtN/A3.28M-
FUNDAMENTALS RATINGS
CLYYF vs IBIO: Fundamental Ratings
CLYYF
IBIO
OUTLOOK RATING
1..100
3687
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
9036
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
2985

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBIO's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for CLYYF (70) in the null industry. This means that IBIO’s stock grew somewhat faster than CLYYF’s over the last 12 months.

IBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLYYF (100) in the null industry. This means that IBIO’s stock grew similarly to CLYYF’s over the last 12 months.

IBIO's SMR Rating (97) in the Biotechnology industry is in the same range as CLYYF (99) in the null industry. This means that IBIO’s stock grew similarly to CLYYF’s over the last 12 months.

IBIO's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for CLYYF (90) in the null industry. This means that IBIO’s stock grew somewhat faster than CLYYF’s over the last 12 months.

IBIO's P/E Growth Rating (99) in the Biotechnology industry is in the same range as CLYYF (100) in the null industry. This means that IBIO’s stock grew similarly to CLYYF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLYYFIBIO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
38%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
36%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
13%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
11%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
N/A
Bullish Trend 27 days ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
30%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CLYYF
Daily Signal:
Gain/Loss:
IBIO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SMHI7.090.22
+3.20%
SEACOR Marine Holdings
MDU20.910.54
+2.65%
MDU Resources Group
SEED1.220.02
+1.67%
Origin Agritech Limited
BCAX17.010.25
+1.49%
Bicara Therapeutics Inc.
MCHP76.66-1.42
-1.82%
Microchip Technology

CLYYF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLYYF has been loosely correlated with ELVAF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CLYYF jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLYYF
1D Price
Change %
CLYYF100%
N/A
ELVAF - CLYYF
47%
Loosely correlated
N/A
REPL - CLYYF
35%
Loosely correlated
+5.81%
IBIO - CLYYF
23%
Poorly correlated
-2.61%
ATHE - CLYYF
22%
Poorly correlated
-2.87%
BNTC - CLYYF
22%
Poorly correlated
+1.04%
More

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with ELVAF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
-2.61%
ELVAF - IBIO
39%
Loosely correlated
N/A
REPL - IBIO
38%
Loosely correlated
+5.81%
VOR - IBIO
36%
Loosely correlated
+0.23%
NUVB - IBIO
34%
Loosely correlated
+4.80%
WVE - IBIO
33%
Poorly correlated
+2.01%
More